Baseline characteristics
| No. of patients . | N = 25 . |
|---|---|
| Age, median (IQR) | 70 (58-75) |
| Sex, male (%) | 14 (56) |
| Days from diagnosis to baseline, median (IQR) | 67 (46-90) |
| Phlebotomies from diagnosis to baseline, median (IQR) | 3 (2-5) |
| High risk, n (%) | 19 (76) |
| Prior thrombosis, n (%) | 5 (20) |
| Splenomegaly, n (%) | 3 (12) |
| Hemoglobin (g/dL), median (IQR) | 13.8 (13.4-15.3) |
| Hematocrit, median (IQR) | 0.44 (0.41-0.48) |
| White blood cell count (×109/L), median (IQR) | 9.9 (7.3-11.4) |
| Platelet count (×109/L), median (IQR) | 415 (275-570) |
| JAK2V617F VAF at diagnosis (%), median (IQR) | 50 (35-65) |
| JAK2V617F VAF at baseline (%), median (IQR) | 54 (21-66) |
| No. of patients . | N = 25 . |
|---|---|
| Age, median (IQR) | 70 (58-75) |
| Sex, male (%) | 14 (56) |
| Days from diagnosis to baseline, median (IQR) | 67 (46-90) |
| Phlebotomies from diagnosis to baseline, median (IQR) | 3 (2-5) |
| High risk, n (%) | 19 (76) |
| Prior thrombosis, n (%) | 5 (20) |
| Splenomegaly, n (%) | 3 (12) |
| Hemoglobin (g/dL), median (IQR) | 13.8 (13.4-15.3) |
| Hematocrit, median (IQR) | 0.44 (0.41-0.48) |
| White blood cell count (×109/L), median (IQR) | 9.9 (7.3-11.4) |
| Platelet count (×109/L), median (IQR) | 415 (275-570) |
| JAK2V617F VAF at diagnosis (%), median (IQR) | 50 (35-65) |
| JAK2V617F VAF at baseline (%), median (IQR) | 54 (21-66) |
IQR, interquartile range.